The dose regimen should achieve a trough level of IgG (measured before the next infusion) of at least 5 to 6 g/l and aim to be within the reference interval of serum IgG for age
Loading dose (if required)
0.2 to 0.5g/kg. This may need to be divided over several days, with a maximal daily dose of 0.1 to 0.15 g/kg
After steady state IgG levels have been attained, maintenance doses are administered to reach a cumulative monthly dose of the order of 0.4-0.8 g/kg
Trough levels should be measured and assessed in conjunction with the incidence of infection
To reduce the rate of infection, it may be necessary to increase the dose and aim for higher trough levels
Dosing and Administration
Dosing and administration1
Primary immunodeficiency syndromes1
The recommended dose administered at repeated intervals (approximately once per week) is to reach a cumulative monthly dose of the order of 0.2-0.4 g/kg.
IgG trough levels should be measured and assessed in conjunction with the incidence of infection
Dose should be adjusted as necessary to achieve optimal protection against infections, an increase may be necessary in patients with persisting infection; a dose decrease can be considered when the patient remains infection free
Cutaquig® should be administered via the subcutaneous route
Cutaquig® can be administered at regular intervals from daily up to every other week
Abdomen, thigh, upper arm, and lateral hip. Infusion sites should be at least 5 cm apart. There is no limit to the number of infusion sites. Each single dose may need to be injected at different anatomic sites
Initially 15 mL/h/site. From infusion 7 on, if well tolerated, the infusion rate can be gradually increased to 25 ml/h/site. Recommended infusion rate per hour for all sites combined: 30 ml/h for first 6 infusions, then gradually increase to 50 ml/h and, if well tolerated to 80 ml/h
Infusion volume per site
Infants and children: infusion site may be checked every 5-15 mL. Adults: doses over 30 mL may be divided according to patient preference
*Please consult your local cutaquig® Summary of Product Characteristics for more detailed instructions.
The low viscosity of cutaquig® makes it easy to use and administer2
1. Cutaquig® Summary of Product Characteristics. January 2022.
2. Gelbmann, N., et al., Octanorm [cutaquig®], a new immunoglobulin (human) subcutaneous 16.5% solution for injection (165 mg/mL) – biochemical characterization, pathogen safety, and stability. Biologicals, 2019. 60:60-67.
This is an international website for cutaquig® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
▼ This medicinal product is subject to additional monitoring.